Dual antiplatelet treatment

Česká verze

Authors: J. Krupička
Authors place of work: Kardiochirurgické oddělení Nemocnice na Homolce Praha, vedoucí oddělení prim. MUDr. Štěpán Černý, CSc.
Published in the journal: Vnitř Lék 2008; 54(10): 985-991
Category: Přehledné referáty

Summary

Atherothrombosis is the most frequent cause of cerebrovascular and cardiovascular incidents. In spite of indisputable progress in treatment the residual risk remains high. Further means are needed to improve the prognosis for patients. Just as in the treatment of hypertension or dyslipidemia we are presently going down the route of combined medication, which affects the thrombosis process at different stages and thus increases the final effect. The article summaries the current possibilities for dual antiplatelet treatment and its indications.

Key words:
Dual antiplatelet treatment – atherothrombosis – acetylsalicylic acid – dipyridamole – clopidogrel

Zdroje

1. Fejfar Z, Přerovský I. Klinická fyziologie krevního oběhu. 3. přepracované a rozšířené vyd. Praha: Galén 2002.

2. Murray CJL, Lopez AD (eds). Global Burden of Disease. Vol 1. Boston, MA: Harvard University Press 1996.

3. Zemřelí 2005. Zdravotnická statistika Ústavu Zdravotnických Informací a Statistiky ČR. Available online at http://www.uzis.cz.

4. Bhatt DL, Steg PG, Ohman EM et al, on behalf of the REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180–189.

5. Marek J et al. Farmakoterapie vnitřních nemocí. 3. přepracované vyd. Praha: Grada Publishing 2005.

6. Patrono C, Bachmann F, Baigent C et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of the antiplatelet agents in patiens with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 2004; 25: 166–181.

7. Sacco RL, Adams R, Albers G et al. Guidelines for Prevention of Stroke in Patients with Ischemic Stroke or Transient Ischemic Attack. A Statement for Healthcare Professionals from the American Heart Association/American Stroke Association Council on Stroke Co-Sponsored by the Council on Cardiovascular Radiology and Intervention. Circulation 2006; 113: e409–e449.

8. Wiviott SD, Braunwald E, McCabe CH et al, TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–2015.

9. Wiviott SD, Trenk D, Frelinger AL et al, for the PRINCIPLE-TIMI 44 Investigators. Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention. The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation 2007; 116: 2923–2932.

10. Grines CL, Bonow RO, Casey DE Jr et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115: 813–818.

11. King SB, Smith SC, Hirshfeld JW et al. 2007 focused update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: (2007 Writing Group to Review New Evidence and Update the 2005 ACC/AHA/SCAI Guideline Update for Percutaneous Coronary Intervention). Circulation 2008; 117: 261–295.

12. Bhatt DL, Fox KAA, Hacke W et al, for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706–1717.

13. Pfeffer MA, Jarcho JA. The charisma of subgroups and the subgroups of CHARISMA. N Engl J Med 2006; 354: 1744–1746.

14. American College of Cardiology. Dangers of stopping clopidogrel (Plavix®) for patients with stents and certain other conditions. A public health alert from the American College of Cardiology. Issued March 16, 2005. Available online at www.acc.org.

15. American Heart Association. American Heart Association statement: patient guidance based on results of the CHARISMA trial. Issued march 15, 2006. Available online at www.americanheart.org.

16. ESC statement on the CHARISMA Trial on Clopidogrel (Plavix®): Patients should continue treatment as advised by their physicians. Issued March 17, 2006. Available online at www.escardio.org

17. Purkayastha S, Athanasiou T, Malinovski V et al. Does clopidogrel affect outcome after coronary artery bypass grafting? A meta‑analysis. Heart 2006; 92: 531–532.

18. Wang TH, Bhatt DL, Fox KA et al. An analysis of mortality rates with dual antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J 2007; 28: 2200–2207.

19. Alexander KP, Chan AY, Roe MT et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non‑ST‑segment elevation acute coronary syndromes. JAMA 2005; 294: 3108–3116.

20. Manoukian SV, Feit F, Mehran R et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007; 49: 1362–1368.

21. McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug‑eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519–1521.

22. Eisenstein EL, Anstrom KJ, Kong DF et al. Clopidogrel use and long‑term clinical outcomes after drug‑eluting stent implantation JAMA. 2007; 297: 159–168.

23. Pfisterer M, Brunner-LaRocca HP, Buser PT et al, for trhe BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug‑eluting stents. J Am Coll Cardiol 2006; 48: 2584–2591.

24. Kaiser C, Brunner-La Rocca HP, Buser PT et al. BASKET Investigators. Incremental cost‑effectiveness of drug‑eluting stents compared with a third-generation bare‑metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005; 366: 921–929.

25. Colombo A, Corbett SJ. Drug‑Eluting Stent Thrombosis: Increasingly Recognized But Too Frequently Overemphasized. J Am Coll Cardiol 2006; 48: 203–205.

26. Nordmann AJ et al. Mortality in randomized controlled trials comparing drug‑eluting vs. bare metal stents in coronary artery disease: a meta‑analysis. Eur Heart J 2006; 27: 2784–2814.

27. US Food and Drug Administration. Circulatory System Devices Panel. Available at http://www.fda.gov/ohrms/dockets /ac/cdrh06.html#circulatory. Accessed December 21, 2006.

28. Norrving B. Dipyridamole with aspirin for secondary stroke prevention. Lancet 2006; 367: 1638–1639.

29. Diener HC, Darius H, Bertrand-Hardy JM et al. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract 2001; 55: 162–163.

30. Fischer M, Davalos A. The MATCH study results in the context of secondary stroke prevention. Stroke 2004; 35: 2609.

31. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665–1673.

32. Snoep JD, Hovens MMC, Eikenboom JCJ et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: A systematic review and meta‑analysis. Arch Intern Med 2007; 167: 1593–1599.

33. Campbell ChL, Smyth S, Montalescot G et al. Aspirin Dose for the Prevention of Cardiovascular Disease. JAMA 2007; 297: 2018–2024.